Notable Wednesday Option Activity: COP, FLGT, MS

Fulgent Genetics (FLGT) saw 1,085 option contracts trade today (≈108,500 underlying shares), about 52.7% of its one‑month average daily volume (205,750 shares), driven almost entirely by 1,068 contracts in the $25 put expiring April 17, 2026 (≈106,800 shares). Morgan Stanley (MS) recorded 24,708 option contracts (≈2.47 million underlying shares), roughly 51% of its one‑month ADTV (4.8 million shares), led by 1,169 contracts in the $185 call expiring January 16, 2026 (≈116,900 shares). The flows indicate concentrated positioning in a deep put for FLGT and a deep call for MS, representing notable intraday option activity relative to each stock’s liquidity but not necessarily a company‑specific fundamental announcement.

Analysis

Market structure: The outsized option flows (FLGT ~108.5k shares = 52.7% ADV; MS ~2.5M shares = 51% ADV) imply dealer delta-hedging will be a dominant short-term price driver — heavy FLGT put demand pressures the stock via hedging sell orders, while MS call buying should mechanically support MS via hedging buy orders. Direct winners are liquidity providers and directional option buyers; owners of FLGT equity are short-term losers if puts represent directional bets. These flows matter more for FLGT (small-cap liquidity) than MS (large-cap depth), so price impact per notional is asymmetric.

Risk assessment: Tail risks include biotech-specific adverse catalysts for FLGT (FDA, revenue restatements, litigation) and regulatory/market-structure events for banks (capital rules, sudden credit spread widening) for MS. Immediate (days) risk is volatility spike from dealer hedging; short-term (weeks–months) is IV re-pricing and potential forced liquidation; long-term (quarters) fundamentals will reassert. Hidden dependency: option blocks may be hedges for large institutional stock positions — heavy put volume does not equal naked bearish conviction.

Trade implications: Tactical plays should front-run delta flows but size conservatively: favor defined-risk option structures on FLGT (long-dated put spreads) to limit capital; on MS prefer directional exposure via calls or equity to harvest hedging flows. Monitor put/call skew and open interest changes for 3–5 trading days as an entry signal; expect 5–15% short-term move windows from hedging alone. Portfolio tilt: increase large-cap bank exposure relative to small-cap biotech until implied vols normalize.

Contrarian angles: Consensus reads FLGT flow as pure bearishness, but if flows hedge an existing long position, a volatility unwind could produce a sharp mean reversion rally — risk of being short into a squeeze. For MS, heavy call volume can be dealer-driven and leave asymmetrical risk if macro liquidity tightens. Historical parallel: 2018 single-stock option blocks produced 10–20% short-term swings in small caps; similar magnitude is plausible again. Unintended consequence: crowded hedges can amplify moves and then reverse violently on option expiration or block unwinds.

Key Decisions for Investors

• Establish a defined-risk bearish trade on FLGT: buy Apr 17, 2026 FLGT $25/$15 put spread sized so max loss = 1% of portfolio (size proportional to risk budget). Exit/roll if FLGT trades above $30 for five consecutive sessions or if open interest on these puts falls >50% in 7 trading days.
• Establish a tactical long on MS: buy Jan 16, 2026 MS $185 calls or purchase MS shares equal to 2–3% portfolio exposure. Take profits at +30–40% and cut to -12% loss; if daily MS option flow >50% ADV persists for 3 days, add 25% to position to ride dealer buy-hedging.
• Pair trade (relative value): Long MS equity 2% vs short FLGT equity 1% (or long MS calls vs FLGT put-spread) to capture asymmetric flow-driven moves while limiting net market beta. Rebalance if pair P/L moves >8% intraday or if IV skew compresses by >20% within 10 trading days.
• Risk/monitor trigger: Track single-stock option volume as % of ADV and IV skew daily; if FLGT option volume >40% ADV for 3 consecutive sessions or IV rises >30% QoQ, widen hedges (increase protection to 2% portfolio) and reduce small-cap biotech beta by 50% within 5 trading days.